Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Account Payables (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Change in Account Payables data on record, last reported at $162000.0 in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 57.14% year-over-year to $162000.0; the TTM value through Dec 2025 reached -$869000.0, down 176.16%, while the annual FY2025 figure was -$869000.0, 176.16% down from the prior year.
  • Change in Account Payables reached $162000.0 in Q4 2025 per CTNM's latest filing, up from -$1.2 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.8 million in Q1 2025 and bottomed at -$1.6 million in Q2 2025.
  • Average Change in Account Payables over 3 years is $22666.7, with a median of $166000.0 recorded in 2024.
  • The widest YoY moves for Change in Account Payables: up 2720.0% in 2025, down 1067.06% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at -$625000.0 in 2023, then skyrocketed by 160.48% to $378000.0 in 2024, then crashed by 57.14% to $162000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $162000.0 in Q4 2025, -$1.2 million in Q3 2025, and -$1.6 million in Q2 2025.